Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 498: (TSX: $CWEB.TO) (TSXV: $PCLO.V) (TSXV: $BEER.C) (CSE: $LXX.C)
Delta, Kelowna, BC, November 19, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen
to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/111920-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/11191CWEB-PCLO-BEER-LXX.asp
Hear Investor ideas cannabis potcast on iTunes
Today’s
podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements.
Charlotte's Web
Holdings, Inc. (TSX:
CWEB) (OTCQX:CWBHF), the
market leader in hemp CBD extract
products, announced a
collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical
Sciences to advance hemp cannabinoid science through a research program that
provides a better understanding of the therapeutic uses and safety of
cannabinoids.
This
new scientific initiative builds on early projects that have been envisioned
with Dr. Gene D. Morse, Director of the Center for Integrated Global Biomedical
Sciences (CIGBS) at the University at Buffalo and State University of New York
(SUNY) Distinguished Professor. The new partnership includes collaboration on a
global program to advance cannabinoid sciences implementation research and
safety for both supplement and biomedical use of cannabinoids with the
coordination center at Buffalo, N.Y. Its purpose is to identify optimal
approaches to advance the safe use of cannabinoid-containing products and
identify the gaps in current knowledge. The program will include the design and
implementation of novel population-based clinical informatics analysis using
large databases, pilot projects that facilitate better understanding of
pre-clinical and clinical pharmacology, and drug interactions to develop safe
approaches to cannabinoid therapy.
"Charlotte's
Web's CW Labs has an advanced team of scientists based here on the medical
campus. We are excited to work with the
clear leaders in the hemp sector, both in the quality of their hemp genetics
and their products," said Dr. Morse.
"We
realize the value of partnering our established cannabinoid product business
models with an internationally recognized leader in clinical research to
address the growing field of cannabinoid health and wellness products,"
said Tim Orr, CW Labs' Senior Vice President of Innovation. "This
collaboration will oversee multidisciplinary teams conducting cutting edge research
in new areas of implementation to expand the database of evidence that can
guide future therapeutics development in the field. We are pleased to have
established this working relationship with UB's Center for Integrated Global
Biomedical Sciences and the opportunity that this new alliance creates."
Building
of this multi-disciplinary team is underway. It includes UB investigators: Dr.
Laszlo Mechtler, a Neurologist and Neuro-oncologist in the department of
Neurology, Medical Director of the Dent Neurologic Institute and it's Cannabis
Clinic and Research Center, as well as the Chief of Neuro-Oncology at Roswell
Park Comprehensive Cancer Center, Dr. Jason Sprowl, a pharmaceutical scientist
in the department of Pharmaceutical Sciences at UB, investigators at the University of the West
Indies, Mona Campus, Jamaica, Dr.
Marvin Reid, director of the Tropical Medicine Research Institute, Professor
Thejani Delgoda, who leads the Natural Products Institute, and Professor Wendel
Abel of Community Health and Psychiatry. At the University of Zimbabwe,
Professor Charles Maponga, Director of the Clinical Pharmacology Laboratory, is
engaged with planning clinical research and related regulatory policies to
promote safe cannabinoid use.
The
collaboration will pursue implementation research related to the wellness
aspects of cannabinoids through the established national and global
capacity-building efforts that form the foundation of the UB Center for
Integrated Global Biomedical Sciences. This includes programs that have been
developed with the Dent Neurologic Institute, home to one of the nation's
largest and most comprehensive physician-directed medical cannabis programs
with more than 15,000 active patients, the University of the West Indies, Mona
Campus in Jamaica, and the University of Zimbabwe Center of Excellence in
Pharmaceutical Innovation in the developing Health Galaxy Park site in Harare,
Zimbabwe. The goal is to build a global collaboration of partners with an
interest in cannabinoid sciences that includes pre-clinical and translational
pharmacology, human safety, and community-based health informatics.
"These
scientists bring global expertise in areas such as cellular transport mechanisms
that influence cannabinoid distribution throughout the body, clinical
pharmacology mechanisms that contribute to different responses among
individuals and potential interactions between botanical cannabinoids and
commonly used medications and will contribute to a global understanding of
cannabinoids" said Dr. Morse.
Dr.
Morse, and Dr. Jeffrey C. Lombardo, Program Coordinator for Global Cannabinoid
Sciences, will lead the collaboration with CW Labs. Dr. Morse, Director of the
Translational Pharmacology Research Core and co-Director of the Drug
Development Center at UB, has extensive experience with pharmacologic assay
development, designing, implementing and analyzing clinical trials with
pharmacokinetics and pharmacodynamics. The collaboration with CW Labs Inc. will
create a novel partnership with the Global Cannabinoids Research program at the
Center for Integrated Global Biomedical Sciences.
PharmaCielo
Ltd. (TSXV:
PCLO) (OTCQX:
PCLOF) and MINO Labs S.A. de C.V., the founders of
PharmaCielo S.A. de C.V., congratulate Mexican
Senate members for advancing the much-needed cannabis legislation and
subsequent reform by voting to move forward the legalization bill, which
includes provision for import of medicinal extracts and products.
David Attard, CEO of PharmaCielo
Ltd., says, "The recent vote is an important development and positive
momentum toward bringing cannabis reform to the finish line by the mid-December
deadline. The partnership we established with MINO Labs last year as
PharmaCielo Mexico is a precursor to what we expect will become an important
and vibrant market for cannabis-derived health and wellness products, for which
we aim to become a primary supplier of high-quality medicinal-grade oils and
isolates."
Manuel Cosme Odabachian, CEO of MINO
Labs, stated, "Mexican lawmakers made it loud and clear today that adult
cannabis usage should be legalized. The Senators' votes in favor of the new
bill are a huge step forward and a development welcomed by both end-users and
industry participants. For the past 20 years, MINO Labs has been a leading
specialty supplier and distributor of pharma-grade products in Mexico. Together
with PharmaCielo we have built a great infrastructure to provide the Mexican
market with top-notch cannabis extract product offerings – and we are ready to
deliver!"
PharmaCielo and MINO Labs founded
PharmaCielo Mexico last year as a joint venture. The purpose of the joint
venture is to bring PharmaCielo's high-quality cannabis extracts and derivative
products from its Colombian cultivation and processing centre to the Mexican
market by leveraging MINO Labs' extensive experience and broad presence in the
country's pharma distribution space. Upon completion of the legislative process,
PharmaCielo Mexico will commence the sale and distribution of medicinal
cannabis products, including those for wellness and lifestyle segments, in
Mexico.
Distribution of cannabis products by
PharmaCielo in Mexico will be subject to the approval of the TSX Venture
Exchange (the "TSXV").
Hill
Street Beverage Company Inc. (TSXV:
BEER) announced that it
has signed a definitive agreement to acquire the primary assets of Lexaria
Canpharm, the cannabis-related division of Lexaria
Bioscience Inc. (CSE:
LXX). This acquisition provides Hill Street with the
exclusive rights in perpetuity to use Lexaria's ground-breaking DehydraTECHTM
patent portfolio on a global basis to make any type of products containing THC
and other psychoactive cannabinoids. In addition, the agreement expands Hill
Street's license with Lexaria HempCo to make products containing CBD on a
global basis for ten years.
Terms of the acquisition
●
Total
consideration of $3.85 million, including $350K in cash upon closing and future
payments of $2.0 million.
●
Hill
Street will issue Lexaria Bioscience a total of $1.5MM worth of Common Shares
in the capital of the Company in three equal installments with the first
tranche issuable on closing. The first tranche will be issued at a price of
$0.0829 per share, which is equal to the 10-day volume weighted average closing
price of the Common Shares on the TSX Venture Exchange on the date hereof. All
successive issuances shall be issued at the greater of (A) the 10-day volume
weighted average closing price of the Common Shares on the TSX Venture Exchange
on such payment date; and (B) $0.0829;
With over sixty patents for
DehydraTECHTM either issued or pending, this transaction positions Hill Street
to expand its strategy of producing ingredients for Cannabis 2.0 products,
allowing the Company to take advantage of growing demand for "quick onset
and duration" recreational cannabis edibles and topicals. This transaction
will allow Hill Street to expand its addressable market to every country in the
world where cannabis is either medicinally or recreationally legal. Lexaria's
Intellectual Property converts perishable cannabis products such as oils and
extracts into shelf stable powders. Hill Street will manufacture these powders
for sale to licensed cannabis processors at its own facility as well as
sub-license the technology to licensed manufacturers globally. Shelf stable
cannabis powders are the ideal ingredients upon which to build world class
Cannabis 2.0 brands, including beverages, edibles, and topicals. The
DehydraTECHTM processes are well researched, market validated, and well
protected through multiple patents, and will continue to improve as Lexaria
continues its research.
Completion of the transaction is
subject to the approval of the TSX Venture Exchange.
"With this transaction, we are
building on an already strong partnership with Lexaria. We are gaining full
ownership of the joint manufacturing partnership we created last year, and
positioning Hill Street to become an early leader in the global market for
cannabis 2.0 ingredients and products. Our cannabis processing facility is
designed specifically to produce shelf stable ingredients using DehydraTECHTM
for the Cannabis 2.0 market," said Terry Donnelly, Chairman & CEO of
Hill Street. "With a significant portion of the consideration in shares
and future payments, this transaction demonstrates Lexaria's faith in Hill
Street to unlock the value of their innovations for their shareholders based on
our success."
"Hill Street's team is
executing a new and exciting strategy in the cannabis sector, designed to take
advantage of the Cannabis 2.0 market and enhanced consumer expectations,"
stated Chris Bunka, Chairman & CEO of Lexaria Bioscience. "Their deep
expertise in consumer goods will allow consumers to experience Lexaria's
innovations through the highest performance products available in the Cannabis
2.0 sector. Lexaria's focus remains on creating the greatest innovations
possible in drug delivery in the diverse sectors of nicotine, cannabinoids, and
antivirals for both the therapeutic and pharmaceutical industries. Innovations
in drug delivery in the pharmaceutical industry represents a massive global
opportunity for Lexaria, and this transaction with Hill Street assists our
ability to focus, while providing our shareholders with a significant carried
interest in a fast growing startup well positioned for success in the cannabis
2.0 market."
Canndora, the global media
and event platform, and initiative created by Marigold Marketing & PR to
support advancing women in emerging industries has announced it is
hosting #CanndoraConnect: Women in Psychedelics event.
A virtual event,
#CanndoraConnect: Women in Psychedelics is open to audiences worldwide and will
take place 2:00-4:00 p.m. EST on Wednesday, December 2nd, 2020. The event will
offer attendees a unique experience, providing collaboration, networking,
inspiration, and advice for women's success in the emerging psychedelics
industry worldwide.
“We are honoured to
be partnering with Canndora to create a movement that is bringing awareness and
attention to advancing women in the emerging psychedelics industry,” says Todd
Shapiro, CEO & Director of Red Light Holland. “This is an exciting event
that will provide amazing opportunities to network, learn, connect and feel
inspired by all of the extraordinarily intelligent speakers and panellists,
including Ann Barnes and Sarah Hashkes, whom we are proud and grateful to work
so closely with at Red Light Holland.”
Attendees will hear
from influential speakers, learn best industry practices for success, and
network with leading industry experts in psychedelics. The event will feature
notable industry professionals and panelists who will share their expertise on
critical topics, including opportunities for international business in
psychedelics and the science behind psilocybin and its role in women's health.
Industry leaders
and speakers in attendance include:
● Ann
Barnes, Director of Red Light Holland
●
Sarah Hashkes, CEO of Radix Motion
●
Terri Smith, Chief Mycologist of WAKE
●
Dr. Olga Chernoloz, Chief Scientific
Officer of WAKE
●
Susan Chapelle, President of Havn Life
● Irie
Selkirk, Co-founder & Director of Rise Wellness Retreats
“2020 is the year
the voice of psychedelic renaissance has been heard the loudest,” says Dr. Olga
Chernoloz, Chief Scientific Officer of WAKE. “So far the data streaming from
the psychedelic clinical studies has been exceptionally promising. It gives
hope to the development and recognition of new treatment modalities for the
support of mental health. Women, often disproportionately affected by these
conditions, could find a way to re-process the underlying emotional content and
find balance with help of the psychedelic-assisted therapy.”
Now hosting its
seventh professional event for emerging industries, including sell-out
attendance in previous cannabis women-focused events, the #CanndoraConnect:
Women and Psychedelics event is positioned to be a hailed success. The event is
made possible with support from presenting partners, Red Light Holland (CSE:
TRIP) (OTC:
TRUFF) and WAKE.
The #CanndoraConnect:
Women in Psychedelics event is open to anyone 19+. Tickets are CAD$15.00 and
attendees are encouraged to register as soon as possible as spaces are limited.
To purchase tickets, register on Eventbrite.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts
is now a certified word mark Trademark on the blockchain through Cognate, Inc.
CM Certification-Registration Number: 10468217708
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
